Data Monitoring Committees Are Useful For High-Risk Phase I/II Trials – FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA strongly recommends data monitoring committees for early-phase clinical trials where the investigator is also the sponsor, or where subjects may be placed at unusual risk, a Nov. 16 draft guidance on DMCs states
You may also be interested in...
FDA Releases Final Guidance On External Clinical Study Monitors
Final guidance issued by FDA March 28 acknowledges device company concerns about the burden of clinical trial data monitoring committees, but stops short of acquiescing to requests to substantially change its 2001 draft recommendations
FDA Releases Final Guidance On External Clinical Study Monitors
Final guidance issued by FDA March 28 acknowledges device company concerns about the burden of clinical trial data monitoring committees, but stops short of acquiescing to requests to substantially change its 2001 draft recommendations
Drug-Coated Stents, Distal Protection Devices: DCRD Explicates DMC Benefits
Device firms employing data monitoring committees to evaluate clinical trials should ensure that DMCs operate under a clearly defined protocol, according to CDRH's Division of Cardiovascular & Respiratory Devices